MYCN and cancer: AURKA forms a complex with N-Myc, which protects N-Myc from FBW7-mediated proteasomal degradation.14 Two AURKA inhibitors, MLN8054 and MLN8237, disrupt the Myc–AURKA complex, resulting in N-Myc degradation and tumor regression in MYCN-amplified neuroblastomas.14, 51 MLN8237 also induced c-Myc degradation in P53-mutant human hepatocellular carcinoma cells.52 These data suggest that AURKA inhibitors may be potential therapeutics for the treatment of Myc-dependent cancers.